A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety and Immunogenicity of a Booster Dose of PIKA Recombinant SARS-CoV-2 Vaccine in Adults Who Received 2 or More Doses of Inactivated Covid-19 Vaccine
Latest Information Update: 26 Jul 2024
At a glance
- Drugs YS SC2 010 (Primary) ; BBIBP CorV
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors LakeShore Biopharma; Yisheng Biopharma
Most Recent Events
- 23 Jul 2024 Status changed from active, no longer recruiting to completed.
- 24 May 2024 According to a YS Biopharma media release, YS Biopharma company name changed to LakeShore Biopharma.
- 26 Feb 2024 Planned End Date changed from 11 Mar 2024 to 11 Apr 2024.